drugset / Trial / NCT03446599
Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a pilot study to determine the hemodynamic effects when hydroxocobalamin vs methylene blue is administered during cardiopulmonary bypass in patients at risk of vasoplegia by measuring mean arterial pressure (MAP), systemic vascular resistance (SVR) and vasopressor requirement.
Timeline
- Start
- 2019-11
- Primary completion
- 2020-05
- Completion
- 2020-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxocobalamin | Unknown | 5 g | Intravenous |
| Subject | Methylene Blue | Diagnostic / imaging agent | 2 mg/kg | Intravenous |